Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment

Bell, Katy J L

Duerr, Hans Peter

Farris, Maria

Glasziou, Paul

Hayen, Andrew

Irwig, Les

Mitchell, Andrew S.

Mitchell, Paul

Wright, Jonathan

Retina

English

Bell, Katy J.L.

Mitchell, Andrew S

Duerr, Hans-Peter

Sydney eScholarship

Early CRT monitoring using time-domain optical coherence tomography does not add to visual acuity for predicting visual loss in patients with central retinal vein occlusion treated with intravitreal Ranibizumab

PURPOSE: Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment.METHODS: The authors used data from 325 participants in the CRUISE study, which included measurement of time-domain CRT and BCVA at baseline, 1 week, 1 month, and 6 months postrandomization. Analysis of covariance models were fitted to assess clinical validity, and distributions of change were constructed to assess detectability of response.RESULTS: There was no evidence that 1-week CRT, and very strong evidence that 1-week BCVA were associated with baseline-adjusted BCVA at 6 months (P = 0.17 and P &lt; 0.001, respectively). There was strong evidence that both 1-month CRT and 1-month BCVA were associated with baseline-adjusted 6-month BCVA (P = 0.005 and P &lt; 0.001, respectively), but simultaneous adjustment found evidence of independent association only for BCVA (P = 0.71 and P &lt; 0.001 for CRT and BCVA, respectively). Detectability of response tended to be higher for CRT than BCVA at 1 week and 1 month but by 6 months these were equivalent for CRT and BCVA.CONCLUSION: In this study, BCVA monitoring of treated central retinal vein occlusion patients seemed more informative than time-domain optical coherence tomography monitoring.This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</p

Bond University Research Portal

Early CRT monitoring using time-domain optical coherence tomography does not add to visual acuity for predicting visual loss in patients with central retinal vein occlusion treated with intravitreal ranibizumab:A secondary analysis of trial data

Katy J. L. Bell

Andrew Hayen

Paul Glasziou

Andrew S. Mitchell

Maria Farris

Jonathan Wright

Hans-Peter Duerr

Paul Mitchell

Les Irwig

Crossref

EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB

https://pure.bond.edu.au/ws/files/10461227/Early_CRT_monitoring_using_time.pdf

Early CRT monitoring using time-domain optical coherence tomography does not add to visual acuity for predicting visual loss in patients with central retinal vein occlusion treated with intravitreal ranibizumab:A secondary analysis of trial data

Abstract

Similar works

Full text

Available Versions

Sydney eScholarship

Bond University Research Portal

Crossref